Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P49406
UPID:
RM19_HUMAN
Alternative names:
39S ribosomal protein L15, mitochondrial; 39S ribosomal protein L19, mitochondrial
Alternative UPACC:
P49406; Q53TX9; Q96Q52
Background:
The Large ribosomal subunit protein bL19m, also known as 39S ribosomal protein L15 and L19, mitochondrial, plays a crucial role in protein synthesis within mitochondria. Its involvement in the mitochondrial ribosome's structure suggests a pivotal function in mitochondrial gene expression.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein bL19m could open doors to potential therapeutic strategies. Its fundamental role in mitochondrial function highlights its potential as a target for diseases linked to mitochondrial dysfunction.